Keros Therapeutics Inc (NASDAQ: KROS) is -30.89% lower on its value in year-to-date trading and has touched a low of $9.77 and a high of $73.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The KROS stock was last observed hovering at around $10.90 in the last trading session, with the day’s gains setting it 0.04%.
Currently trading at $10.94, the stock is 0.64% and -17.27% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.29 million and changing 0.32% at the moment leaves the stock -74.68% off its SMA200. KROS registered -82.80% loss for a year compared to 6-month loss of -75.96%.
The stock witnessed a -4.45% gain in the last 1 month and extending the period to 3 months gives it a -79.68%, and is 3.11% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.10% over the week and 4.09% over the month.
Keros Therapeutics Inc (KROS) has around 136 employees, a market worth around $443.15M and $0.65M in sales. Profit margin for the company is -27890.94%. Distance from 52-week low is 11.92% and -85.01% from its 52-week high. The company has generated returns on investments over the last 12 months (-33.00%).
The EPS is expected to grow by 4.89% this year
The shares outstanding are 39.26M, and float is at 32.83M with Short Float at 12.97%.
The top institutional shareholder in the company is FMR LLC with over 4.72 million shares valued at $$215.69 million. The investor’s holdings represent 16.0279 of the KROS Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 2.51 million shares valued at $$114.86 million to account for 8.5348 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 1.76 million shares representing 5.967 and valued at over $$80.3 million, while ALKEON CAPITAL MANAGEMENT LLC holds 4.4287 of the shares totaling 1.6 million with a market value of $$73.07 million.
Keros Therapeutics Inc (KROS) Insider Activity
The most recent transaction is an insider sale by GORDON CARL L, the company’s Director. SEC filings show that GORDON CARL L sold 250,000 shares of the company’s common stock on Aug 13 ’24 at a price of $44.01 per share for a total of $11.0 million. Following the sale, the insider now owns 0.12 million shares.
Keros Therapeutics Inc disclosed in a document filed with the SEC on Aug 13 ’24 that ORBIMED ADVISORS LLC (Director) sold a total of 250,000 shares of the company’s common stock. The trade occurred on Aug 13 ’24 and was made at $44.01 per share for $11.0 million. Following the transaction, the insider now directly holds 0.12 million shares of the KROS stock.
Still, SEC filings show that on Aug 13 ’24, OrbiMed Genesis Master Fund, L (Shareholder) Proposed Sale 29,400 shares at an average price of $44.84 for $1.32 million. The insider now directly holds shares of Keros Therapeutics Inc (KROS).
